Tags : Riximyo

Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch

Vartika Singh August 19, 2020

Shots: In Jul 2020, following the pCPA agreement Riximyo is now reimbursed through Limited Use as well as the Exceptional Access Program while funding will be done by Cancer Care Ontario. Additionally, from Aug 01, 2020, the BC cancer will be responsible for reimbursement of Riximyo as per British Columbia The patient support program will […]Read More

Biosimilars

Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim)

Tuba Khan June 10, 2020

Shots: Health Canada has approved Ziextenzo (a biosimilar referencing Neulasta) and Riximyo (a biosimilar referencing Rituxan) for marketing in Canada Sandoz has received Health Canada’s Notice of Compliance on Apr 21, 2020, for the use of Ziextenzo to reduce the incidence of febrile neutropenia while Riximyo has received approval on Apr 28, 2020 to treat […]Read More

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Biocon Biologics and Viatris Receive CHMP’s Positive Opinion for Abevmy (biosimilar, bevacizumab)

Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Roche’s Actemra/RoActemra (tocilizumab) Receives the US FDA’s Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Tags : Riximyo

Sandoz Canada Negotiated with Pan-Canadian Pharmaceutical Alliance (pCPA) to Launch

Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim)

Latest Posts

PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Roche’s Actemra/RoActemra (tocilizumab) Receives the US FDA’s Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease

Tags : Riximyo

Latest Posts

Categories

Related Topics